In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK polyomavirus, which can cause serious complications in some transplant patients.
bCentre for Biostatistics, Manchester Academic Health Science Centre, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, United Kingdom of ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The first Article, 1 a meta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results